-
in the international journal JAMA, and the positive results of H drug Hans-shaped (R) combined with chemotherapy
Time of Update: 2022-10-20
ASTRUM-005 study is a phase III clinical study of anti-PD-1 monoclonal antibody H drug independently developed by Henlius Hans-form ® (serplulimab) combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC), after Professor Cheng Ying reported the results for the first time at the 2022 ASCO Annual Meeting, which attracted widespread attention from global peers, and now has once again appeared on the international top academic stage, reflecting the high recognition of the international academic community.
-
in the international top journal JAMA, H drug Hans-like combination chemotherapy first-line ® treatment of extensive small cell lung cancer positive results were released
Time of Update: 2022-10-13
On September 27, 2022, the international multicenter research led by Professor Cheng Ying, ASTRUM-005 research, one of the world's top four medical journals, Journal of the American Medical Associatio
-
, the positive results of Henlius H drug combined with chemotherapy for first-line treatment of extensive-range small cell lung cancer were released
Time of Update: 2022-09-30
On September 27, 2022, ASTRUM-005, an international multicenter research led by Professor Cheng Ying of Jilin Provincial Cancer Hospital, was published in the Journal of the American Medical Associati
-
Junshi Bio-Toripalimab combined with chemotherapy for first-line treatment of esophageal squamous
Time of Update: 2022-08-15
SHANGHAI, May 16, 2022 /PRNewswire/ -- On May 16, 2022, Junshi Bio announced that the company's self-developed anti-PD-1 monoclonal antibody Toripalimab Injection (Tuoyi® ) in combination with paclitaxel and cisplatin for the first-line treatment of patients with unresectable locally advanced/recurrent or distant metastatic esophageal squamous cell carcinoma (ESCC) was approved by the National Medical Products Administration (NMPA) .
-
The U.S. Food and Drug Administration (FDA) approves Opdivo(R) (nivolumab) in combination
Time of Update: 2022-05-23
SHANGHAI, March 6, 2022 /PRNewswire/ -- On March 4, 2022, Bristol-Myers Squibb (announced that the U. S. Food and Drug Administration (FDA) has approved Opdivo® (nivolumab) 360 mg (intravenous) in co
-
CD30-targeted drug Adcetris combined with chemotherapy: first-line treatment significantly prolongs survival!
Time of Update: 2022-05-02
ECHELON-1 is a randomized, open-label, international phase 3 study in adults with newly diagnosed advanced (stage III or IV) cHL to compare Adcetris combined with chemotherapy AVD (doxorubicin + vincristine) Efficacy and safety of ABVD (doxorubicin + bleomycin + vincristine + dacarbazine) relative to the currently accepted standard-of-care regimen ABVD (doxorubicin + bleomycin + vincristine + dacarbazine) .
-
Paclitaxel liposome was selected as the preferred combination drug for multiple radiotherapy
Time of Update: 2022-05-01
According to guideline recommendations, for operable esophageal cancer, neoadjuvant chemoradiotherapy followed by surgery is the standard treatment; for inoperable esophageal cancer, concurrent chemoradiotherapy is the only radical plan; postoperative adjuvant radiotherapy can improve the local control rate and survival of some patients.
-
Clin Cancer Res: Adavosertib combined with various chemotherapy drugs in the treatment of primary
Time of Update: 2022-01-23
The cohort with the highest response rate was the carboplatin plus Adavosertib group The longest duration of response was in the paclitaxel cohort (12.
Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open-Label, Four-Arm, Phase II Study .
-
-angiogenic drugs combined with chemotherapy bring tumor regression
Time of Update: 2021-12-05
Immediately given oral erlotinib (150mg/day) treatment, the headache symptoms disappeared after 1 month, and the imaging review showed that the lung tumor lesions and intracranial metastases were reduced.
-
or combined chemotherapy with neoadjuvant/adjuvant therapy for resectable NSCLC
Time of Update: 2021-11-14
On November 2, Kangfang Bio-Bio announced that its self-developed new tumor immunotherapy drug AK112 (PD-1/VEGF bispecific antibody) has been approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration to develop single-drug or Combination chemotherapy with neoadjuvant/adjuvant therapy can cut the phase II clinical study of non-small cell lung cancer (NSCLC) .
-
Immunologic drugs combined with chemotherapy, patients with advanced nasopharyngeal cancer can have a longer survival time
Time of Update: 2021-07-31
Before the age of immunotherapy, patients with advanced recurrence and metastasis of nasopharyngeal carcinoma, even with the best chemotherapy drugs, had an average tumor control time of only 7 months and an average survival time of only about 2 years .
-
Efficacy and safety of K drug combined with concurrent radiotherapy and chemotherapy: from the KEYNOTE-799 study
Time of Update: 2021-06-30
This two-cohort, non-randomized controlled study aims to evaluate whether combining pembrolizumab on the basis of concurrent radiotherapy and chemotherapy can bring survival benefits to patients with inoperable stage III .
-
-drug combined with chemotherapy for neoadjuvant significantly improves the rate of complete tumor pathology
Time of Update: 2021-04-18
The 2021 American Association for Cancer Research (AACR) annual meeting will be held on April 10 At the opening, CheckMate-816 clinical research data on non-small cell lung cancer was released at the conference: Compared with chemotherapy alone, operable patients in stage IB~IIIA receive 3 cycles of O-drug combined with chemotherapy before surgery , Can significantly improve tumor pathological complete remission (pCR).
-
Toripalimab is a combination of chemotherapy to treat nasopharyngeal cancer, and China's State Drug
Time of Update: 2021-02-23
Chinese pharmaceutical company Junshi Bio recently announced that China's State Drug Administration (NMPA) has accepted a new supplemental drug application for the first-line treatment of relapsed or metastatic nasopharyngeal cancer with Toripalimab combined chemotherapy.
-
Drug K approved for treatment of triple negative breast cancer in combination with chemotherapy to reduce the risk of disease progression by 35%
Time of Update: 2021-01-21
On the 14th, MSD announced that the FDA has accelerated approval of its heavy PD-1 inhibitor Keytruda in combination with chemotherapy for FDA-approved testing to determine non-removable local relapse or metastasis triple negative breast cancer (TNBC) patients with tumor expression PD-L1 (CPS) ≥10).